Somalia
Tuberculosis profile
| High HIV burden |
Population  2013 10 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 7.7 (5.1–10) 74 (48–95)
Mortality (HIV+TB only) 0.43 (0.26–0.63) 4 (2.5–6)
Prevalence  (includes HIV+TB) 57 (29–95) 548 (280–904)
Incidence  (includes HIV+TB) 30 (27–34) 285 (253–320)
Incidence (HIV+TB only) 0.87 (0.63–1.4) 8.3 (6–14)
Case detection, all forms (%) 43 (39–49)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 5.2 (2.7–7.7) 41 (23–58)
MDR-TB cases among notified pulmonary
TB cases
520 (270–780) 280 (160–400)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 6 538   373
Pulmonary, clinically diagnosed 3 533   0
Extrapulmonary 2 550   0
       
Total new and relapse 12 994    
Previously treated, excluding relapses 312    
Total cases notified 13 306    
Among 6 538 new cases:
272 (4%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 290 (4%) 140 (20%) 693
Laboratory-confirmed RR-/MDR-TB cases     185
Patients started on MDR-TB treatment     30
TB/HIV 2013 Number (%)
TB patients with known HIV status 6 973 (52)
HIV-positive TB patients 195 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 141 (72)
HIV-positive TB patients on antiretroviral therapy (ART) 62 (32)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 88
Previously treated cases, excluding relapse, registered in 2012 71
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 9
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 10
% Funded domestically 0%
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-28 Data: www.who.int/tb/data